1.74 USD
▼-0.07-3.87%
盘后 1.75 +0.57%
2026-09-15
市值
$559.30M
市盈率
—
EPS
-0.56
股息率
—
52 周区间
1.30 – 3.48
成交量
1.20M
Beta
1.75
目标价
6.25
52W 低 1.3052W 高 3.48
价格走势
公司简介
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, a...